✦ LIBER ✦

Treatment of Philadelphia-positive acute lymphocytic leukemia with tyrosine kinase inhibitors: What is the optimal regimen?

✍ Scribed by Amber Fullmer; Elias Jabbour

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 70 KB
Volume: 85
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.21649

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tyrosine kinase inhibitors for the treat

Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia

✍ Pier Paolo Piccaluga; Stefania Paolini; Giovanni Martinelli 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 208 KB

## Abstract Acute lymphoblastic leukemia (ALL) is a heterogeneous disorder, with the greatest prevalence in children, but it also affects adults, and has an increasing incidence with age. Chromosomal abnormalities in ALL have been frequently described, the most common is the Philadelphia chromosome

Treatment of Philadelphia-chromosome-pos

Treatment of Philadelphia-chromosome-positive human leukemia in scid mouse model with herbimycin A, bcr-abl tyrosine kinase activity inhibitor

✍ Yoshio Honma; Yoshinobu Matsuo; Yasuhide Hayashi; Satoshi Omura 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 French ⚖ 731 KB

The molecular basis of the Philadelphia chromosome (Ph') is a structurally altered c-abl (bcr-abl) gene which encodes an abnormally large protein with protein tyrosine kinase activity. Herbimycin A, which effectively reduced intracellular phosphorylation by bcr-abl tyrosine kinase, preferentially in